Rare Disease Advocates Lobby US Congress For FDA Center of Excellence
Number one ask is for congressional pressure to centralize rare disease expertise at the agency, but advocates also are preparing legislation that would mandate the new center.
You may also be interested in...
Rare Disease Challenges At US FDA: CDER Director Says More Staff, Not Reorganization, Will Fix Issues
Rather than changing the agency's structure to create more focus on rare diseases, Patrizia Cavazzoni wants funding for people to do the necessary work.
Oncology Center of Excellence Grows Leadership Structure, With A Vacancy Remaining
A deputy center director position remains open and four new associate director positions were added over the last year.
US FDA’s Human Drugs Program Suffers In Adjustment Of Agency Priorities
President Trump's budget request would boost compounding and vaccines by $5m, but human drugs program would lose $4.8m in training funds.